Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients

Trial Profile

Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2017

At a glance

  • Drugs Rifalazil (Primary)
  • Indications Chlamydial infections; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Acronyms PROVIDENCE-1
  • Sponsors ActivBiotics
  • Most Recent Events

    • 07 Nov 2007 Status change from in progress to completed.
    • 02 Oct 2006 Status change
    • 08 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top